PD Dr. Hubert Nüsslein

Medizinische Fakultät

Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study (2019) Peichl P, Alten R, Galeazzi M, Lorenz HM, Nüsslein H, Navarro F, Elbez Y, et al. Journal article Effectiveness and safety of anti-tumour necrosis factor therapy with certolizumab pegol observed in real-life rheumatoid arthritis patients in Germany: results from the non-interventional FαsT study (2019) Burmester G, Nüsslein H, von Hinüber U, Detert J, Richter C, Kumke T, Leunikava I, et al. Journal article FACTORS ASSOCIATED WITH PERSISTENT DRUG-FREE REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS (2019) Valor L, Hagen M, Reiser M, Kleyer A, Hartmann F, Manger B, Schett G, et al. Conference contribution Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study (Clinical Rheumatology, (2019), 38, 5, (1413-1424), 10.1007/s10067-019-04449-w) (2019) Alten R, Mariette X, Lorenz HM, Nüsslein H, Galeazzi M, Navarro F, Chartier M, et al. Journal article, Erratum Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study (2019) Alten R, Mariette X, Lorenz HM, Nüsslein H, Galeazzi M, Navarro F, Chartier M, et al. Journal article Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries (2019) Alten R, Feist E, Lorenz HM, Nüsslein H, Voll RE, Chartier M, Elbez Y, Rauch C Journal article Cost-effective tapering algorithm in patients with rheumatoid arthritis: Combination of multibiomarker disease activity score and autoantibody status (2019) Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, et al. Journal article ELEVATED MULTI-BIOMARKER DISEASE ACTIVITY (MBDA) PREDICTS RELAPSES IN RA PATIENTS IN SUSTAINED REMISSION TAPERING TUMOUR NECROSIS FACTOR INHIBITOR THERAPY-RESULTS FROM THE RANDOMIZED CONTROLLED RETRO STUDY (2017) Rech J, Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, et al. Conference contribution MULTI-BIOMARKER DISEASE ACTIVITY AND AUTOANTIBODY STATUS LEAD TO COST EFFECTIVE TAPERING ALGORITHMS IN RHEUMATOID ARTHRITIS PATIENTS IN SUSTAINED REMISSION (2017) Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, et al. Conference contribution ANTI-MODIFIED PROTEIN ANTIBODY RESPONSE PATTERN INFLUENCES THE RISK FOR DISEASE RELAPSE IN RHEUMATOID ARTHRITIS PATIENTS TAPERING DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (2016) Figueiredo C, Bang H, Cobra JF, Englbrecht M, Hueber AJ, Haschka J, Manger B, et al. Conference contribution